By Fineline Cube 
China-based Simcere Pharmaceutical Group (HKG: 2096) announced the initiation of a Phase I clinical study for its SIM0686, an antibody drug conjugate (ADC) targeting FGFR2b, in advanced solid tumors. The first patient was dosed at the Nanjing Tianyinshan Hospital.
Study Design and Leadership
The study is co-led by Professor Qin Shukui from Nanjing Tianyinshan Hospital, Professor Li Jin from Shanghai Gaobo Cancer Hospital, and Professor Lin Tongyu from Sichuan Cancer Hospital. It is designed to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of SIM0686 in advanced solid tumors.
SIM0686 Mechanism and Development
SIM0686 exerts anti-tumor effects by targeting FGFR2b inhibition and is being developed for the treatment of advanced malignant tumors such as gastric cancer and lung cancer. In multiple preclinical studies, the drug demonstrated significant anti-tumor efficacy, including tumor regression observed in tumor models resistant to bemarituzumab or with larger volumes.-Fineline Info & Tech